Healthy aging and the blood-brain barrier
Spatial transcriptomics combined with single-cell RNA sequencing identified high expression levels of ferroptosis-related genes, including TFRC, NCO4, and SLC3A2, in granulosa cells of patients with ovarian senescence, while GPX4 expression was notably low (Lin et al., 2023)
Cell Signal 2000;12:113
Factors that may suggest an immune-mediated component and potential benefit from IVIG include: Clinical Features Rapid onset or progression of symptoms Non-length-dependent pattern (symptoms not limited to feet/hands) Associated autonomic symptoms Lack of other evident causes (diabetes, toxins, etc.) Family history of autoimmune disease Laboratory Findings Presence of autoantibodies (even non-specific ones) Elevated inflammatory markers Evidence of complement activation Abnormal immunoglobulin levels or patterns Diagnostic Test Results Skin biopsy showing inflammatory infiltrates along with reduced fiber density Abnormal autonomic testing consistent with SFN Normal or minimally abnormal nerve conduction studies (ruling out large fiber involvement) Response to Initial Therapies Inadequate response to standard neuropathic pain medications Partial response to corticosteroids or other immunosuppressants Temporal association with infections, vaccines, or immune stressors The IVIG Treatment Protocol For patients with refractory SFN who are deemed appropriate candidates, IVIG therapy typically follows a structured protocol: Dosing and Administration Initial treatment: 2 g/kg divided over 2-5 consecutive days Maintenance: 1 g/kg every 3-4 weeks Treatment duration: Initially 3-6 months with periodic reassessment The optimal duration of therapy remains somewhat individualized
Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase
